Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and device for indicating acute myelogenous leukemia medicine

A technology for acute myeloid and leukemia, applied in biochemical equipment and methods, microbial measurement/inspection, proteomics, etc., can solve the problems of cumbersome gene screening process, inability to formulate treatment plan, delay in treatment timing, etc.

Inactive Publication Date: 2018-06-08
EZHOU INST OF IND TECH HUAZHONG UNIV OF SCI & TECH
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the problems existing in the prior art, the embodiment of the present invention provides a method and device for drug indication of normal karyotype acute myeloid leukemia, which is used to solve the process of screening genes due to too many evaluation genes in the prior art. It is cumbersome, and cannot effectively and easily use the evaluation gene to evaluate the prognosis and stratify the disease of CN-AML patients, and cannot indicate the corresponding drug information to the patients of the corresponding level, which leads to the inability to quickly formulate the treatment plan according to the corresponding drug instructions in the clinic, and delays Technical issues with timing of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and device for indicating acute myelogenous leukemia medicine
  • Method and device for indicating acute myelogenous leukemia medicine
  • Method and device for indicating acute myelogenous leukemia medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] This embodiment provides a method for drug indication for acute myeloid leukemia, such as figure 1 As shown, the method includes:

[0074] S110, acquiring gene expression information of a target sample from a database, where the target sample is a sample of a CN-AML patient with normal karyotype acute myeloid leukemia;

[0075] In this step, the gene expression information of a preset number of samples is downloaded from the cancer gene database (TCGA, The Cancer Genome Atlas). The preset samples include: patients with normal karyotype acute myeloid leukemia CN-AML and abnormal karyotype acute myeloid leukemia. The gene expression information of leukemia patients, the gene expression information includes: gene expression amount.

[0076] Here, because in the data, the sample identifications of CN-AML patients and patients with abnormal karyotype acute myeloid leukemia are different, so the gene of the target sample can be extracted from the preset number of samples acc...

Embodiment 2

[0132] Corresponding to Embodiment 1, this embodiment provides a device for acute myeloid leukemia drug indication, such as figure 2 As shown, the device includes: a first acquisition unit 21, a classification unit 22, a first screening unit 23, a second screening unit 24, an analysis unit 25, a verification unit 26, a second acquisition unit 27, a stratification unit 28 and an indication Unit 29; where,

[0133] Before the first acquisition unit 21 acquires the target evaluation gene of the patient with normal karyotype acute myeloid leukemia CN-AML, it needs to first determine which gene the target evaluation gene is, and the specific determination method is as follows:

[0134] The first acquisition unit 21 is used to download and acquire gene expression information of a preset number of samples from the cancer gene database TCGA, and the preset samples include: patients with normal karyotype acute myeloid leukemia CN-AML and patients with abnormal karyotype acute myeloid ...

Embodiment 3

[0171] In practical applications, the target evaluation gene of CN-AML can be determined according to the above method and device, and the gene can be used to stratify the prognosis of CN-AML and indicate the corresponding drug information, as follows:

[0172] First download the gene expression information and clinical information of 200 samples from the TCGA database, and then extract the gene expression information of the CN-AML samples from the preset number of samples according to the sample identification of the CN-AML samples. The number of CN-AML samples is 79 cases.

[0173] According to the preset survival time as the classification standard, the CN-AML samples are divided into the first type of samples and the second type of samples; the preset survival time is an empirical index of clinical complete remission of CN-AML, specifically: 2 years. In this implementation, the first type of samples are CN-AML samples whose survival time is less than 2 years, and the seco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The embodiment of the invention provides a method and a device for indicating an acute myelogenous leukemia medicine. The method comprises the steps of screening a target evaluation gene from a presettarget sample, wherein the target evaluation gene is an STAB1 gene; acquiring target evaluation genes of normal karyotype acute myelogenous leukemia CN-AML patients; layering the CN-AML patients according to gene expression levels of the target evaluation genes of the CN-AML patients, and dividing the CN-AML patients into a favorable prognosis group and an unfavorable prognosis group; indicatingcorresponding medicine information for the CN-AML patients in the unfavorable prognosis group; only one target evaluation gene exists, so that the CN-AML patients can be simply subjected to prognosisevaluation and disease layering; in addition, the target evaluation gene is the STAB1 gene which is a membrane protein gene, so that the gene can be quickly detected by utilizing an existing detectiondevice, and the detection efficiency is improved.

Description

technical field [0001] The invention belongs to the technical field of molecular biology, and in particular relates to a method and a device for drug indication of acute myeloid leukemia. Background technique [0002] Acute myeloid leukemia (AML, Acute Myeloid Leukemia) is a malignant clonal disease characterized by the blockage of hematopoietic stem cell differentiation leading to abnormal proliferation of immature cells at different stages and reduction of normal hematopoietic tissue, which seriously affects human health. [0003] According to the cytogenetic stratification, the prognosis of AML can be divided into low-risk group, intermediate-risk group and high-risk group. Among them, patients with normal karyotype (CN-AML, Cytogenetically normal Acute Myeloid Leukemia) classified in the intermediate-risk group account for about 50% of all AML patients, there is obvious heterogeneity in these patients, and there are obvious differences in prognosis. [0004] At present,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G06F19/18
CPCC12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/156C12Q2600/158G16B20/00
Inventor 郭安源林生彦陈智超苗亚茹
Owner EZHOU INST OF IND TECH HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com